0001209191-19-034804.txt : 20190605 0001209191-19-034804.hdr.sgml : 20190605 20190605170607 ACCESSION NUMBER: 0001209191-19-034804 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190603 FILED AS OF DATE: 20190605 DATE AS OF CHANGE: 20190605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wolff Henry Ward CENTRAL INDEX KEY: 0001302390 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35935 FILM NUMBER: 19880532 MAIL ADDRESS: STREET 1: 6701 KAISER DRIVE CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001269021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-244-6864 MAIL ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-03 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001302390 Wolff Henry Ward C/O PORTOLA PHARMACEUTICALS, INC. 270 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2019-06-03 4 M 0 2000 27.5519 D 0 I By Henry & Marian Wolff 1999 Revocable Trust Common Stock 13766 D Subsequent to Reporting Person's acquisition of 5,000 shares through a cash exercise on March 12, 2019, Reporting Person transferred 2,000 shares into the Henry & Marian Wolff 1999 Revocable Trust for which Reporting Person is a trustee. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2019. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.13 to $27.98, inclusive. The Reporting Person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Mike Ouimette, as attorney-in-fact 2019-06-05